Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Venous Thromboembolism | 5 | 2019 | 4273 | 1.01 | Why? |
| Blood Platelets | 8 | 2018 | 1704 | 1.00 | Why? |
| Thromboembolism | 3 | 2018 | 2101 | 0.84 | Why? |
| Ticlopidine | 3 | 2018 | 193 | 0.72 | Why? |
| Dalteparin | 1 | 2018 | 57 | 0.71 | Why? |
| Receptors, Thrombin | 1 | 2017 | 22 | 0.70 | Why? |
| Carcinoma, Lobular | 1 | 2017 | 62 | 0.69 | Why? |
| Anticoagulants | 7 | 2020 | 9563 | 0.68 | Why? |
| Platelet Function Tests | 1 | 2017 | 231 | 0.63 | Why? |
| Acute Coronary Syndrome | 4 | 2018 | 2107 | 0.62 | Why? |
| Fibrinolysis | 1 | 2021 | 521 | 0.62 | Why? |
| Carcinoma, Ductal, Breast | 1 | 2017 | 149 | 0.62 | Why? |
| Heparin | 2 | 2020 | 2600 | 0.61 | Why? |
| Central Venous Catheters | 1 | 2017 | 188 | 0.59 | Why? |
| Dabigatran | 1 | 2017 | 204 | 0.58 | Why? |
| Extracorporeal Membrane Oxygenation | 4 | 2021 | 5002 | 0.57 | Why? |
| Hemorrhage | 5 | 2021 | 3013 | 0.57 | Why? |
| Thiazoles | 1 | 2018 | 496 | 0.51 | Why? |
| Thrombophilia | 4 | 2020 | 1935 | 0.48 | Why? |
| Blood Coagulation Tests | 1 | 2017 | 855 | 0.47 | Why? |
| Platelet Aggregation | 4 | 2017 | 318 | 0.46 | Why? |
| Blood Cell Count | 1 | 2017 | 1101 | 0.43 | Why? |
| Bariatric Surgery | 2 | 2018 | 1298 | 0.43 | Why? |
| Pancreatic Neoplasms | 1 | 2018 | 609 | 0.43 | Why? |
| Blood Coagulation | 2 | 2021 | 2768 | 0.42 | Why? |
| Thrombin | 3 | 2017 | 325 | 0.41 | Why? |
| Fibrinolytic Agents | 2 | 2017 | 1702 | 0.38 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.38 | Why? |
| Thrombosis | 3 | 2020 | 7504 | 0.34 | Why? |
| Antibodies, Antiphospholipid | 3 | 2020 | 519 | 0.34 | Why? |
| Fibrin Fibrinogen Degradation Products | 3 | 2020 | 5993 | 0.34 | Why? |
| Obesity, Morbid | 1 | 2018 | 1340 | 0.33 | Why? |
| Peptide Fragments | 1 | 2017 | 2075 | 0.32 | Why? |
| Thrombocytopenia | 1 | 2020 | 2093 | 0.32 | Why? |
| Blood Coagulation Disorders | 1 | 2020 | 2040 | 0.32 | Why? |
| Purinergic P2Y Receptor Antagonists | 2 | 2018 | 206 | 0.31 | Why? |
| Ultrasonography, Doppler | 2 | 2020 | 406 | 0.30 | Why? |
| von Willebrand Factor | 2 | 2021 | 668 | 0.28 | Why? |
| Neoplasms | 4 | 2021 | 17251 | 0.25 | Why? |
| Registries | 2 | 2018 | 12327 | 0.22 | Why? |
| Percutaneous Coronary Intervention | 1 | 2017 | 3646 | 0.21 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.20 | Why? |
| Breast Neoplasms | 1 | 2017 | 3633 | 0.19 | Why? |
| Thrombasthenia | 1 | 2018 | 12 | 0.19 | Why? |
| Prospective Studies | 8 | 2021 | 43301 | 0.19 | Why? |
| Ideal Body Weight | 1 | 2018 | 18 | 0.19 | Why? |
| Prasugrel Hydrochloride | 1 | 2018 | 114 | 0.17 | Why? |
| Hirudins | 1 | 2017 | 75 | 0.17 | Why? |
| Breast Neoplasms, Male | 1 | 2017 | 48 | 0.17 | Why? |
| Blood Platelet Disorders | 1 | 2017 | 44 | 0.17 | Why? |
| Platelet Aggregation Inhibitors | 3 | 2017 | 1671 | 0.17 | Why? |
| Survival Analysis | 3 | 2020 | 7592 | 0.16 | Why? |
| Platelet-Rich Plasma | 1 | 2017 | 91 | 0.16 | Why? |
| Perioperative Period | 1 | 2018 | 276 | 0.16 | Why? |
| Cell-Derived Microparticles | 1 | 2017 | 134 | 0.16 | Why? |
| Carotid Arteries | 1 | 2018 | 182 | 0.16 | Why? |
| Drug Therapy | 1 | 2018 | 280 | 0.15 | Why? |
| Neoplasm Metastasis | 1 | 2018 | 682 | 0.14 | Why? |
| Rivaroxaban | 1 | 2018 | 467 | 0.14 | Why? |
| Body Mass Index | 2 | 2018 | 4306 | 0.14 | Why? |
| Fibrinogen | 1 | 2020 | 1048 | 0.14 | Why? |
| Antithrombins | 1 | 2017 | 353 | 0.13 | Why? |
| Humans | 30 | 2021 | 930598 | 0.13 | Why? |
| Wound Healing | 1 | 2017 | 424 | 0.13 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.12 | Why? |
| Pyridines | 1 | 2018 | 680 | 0.12 | Why? |
| Weight Loss | 1 | 2018 | 826 | 0.12 | Why? |
| Body Weight | 1 | 2018 | 1074 | 0.11 | Why? |
| Coronary Artery Bypass | 1 | 2018 | 629 | 0.11 | Why? |
| Fluorobenzenes | 1 | 2010 | 7 | 0.11 | Why? |
| Heptanoic Acids | 1 | 2010 | 13 | 0.11 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.11 | Why? |
| Drug-Eluting Stents | 1 | 2017 | 562 | 0.11 | Why? |
| Neoplasm Recurrence, Local | 1 | 2018 | 1063 | 0.11 | Why? |
| Coronary Vessels | 1 | 2018 | 914 | 0.10 | Why? |
| Antioxidants | 1 | 2020 | 1593 | 0.10 | Why? |
| Male | 13 | 2021 | 367725 | 0.10 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2019 | 1731 | 0.10 | Why? |
| Female | 11 | 2021 | 380317 | 0.10 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.09 | Why? |
| Pyrazoles | 1 | 2018 | 1791 | 0.09 | Why? |
| Incidence | 3 | 2020 | 25622 | 0.09 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.08 | Why? |
| Pyrroles | 1 | 2010 | 292 | 0.08 | Why? |
| Sulfonamides | 2 | 2020 | 1294 | 0.08 | Why? |
| Biomarkers | 3 | 2020 | 23361 | 0.08 | Why? |
| Recombinant Proteins | 1 | 2017 | 3786 | 0.08 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.08 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.08 | Why? |
| Atrial Fibrillation | 2 | 2018 | 2320 | 0.08 | Why? |
| Risk | 1 | 2018 | 5288 | 0.07 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.07 | Why? |
| Venous Thrombosis | 1 | 2020 | 2739 | 0.07 | Why? |
| Asymptomatic Diseases | 1 | 2017 | 3444 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.07 | Why? |
| Adult | 6 | 2021 | 244371 | 0.06 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.06 | Why? |
| Stents | 1 | 2010 | 916 | 0.06 | Why? |
| Patient Discharge | 1 | 2018 | 5696 | 0.06 | Why? |
| Pyrimidines | 1 | 2010 | 1557 | 0.06 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.06 | Why? |
| Retrospective Studies | 4 | 2020 | 105322 | 0.05 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.05 | Why? |
| Proteinase Inhibitory Proteins, Secretory | 1 | 2020 | 43 | 0.05 | Why? |
| Risk Factors | 3 | 2020 | 71621 | 0.05 | Why? |
| Superoxide Dismutase | 1 | 2020 | 155 | 0.05 | Why? |
| Critical Illness | 2 | 2020 | 17281 | 0.05 | Why? |
| Spain | 1 | 2018 | 15545 | 0.05 | Why? |
| Glycine | 1 | 2020 | 203 | 0.05 | Why? |
| Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
| Adenosine Diphosphate | 1 | 2018 | 63 | 0.05 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.05 | Why? |
| Acetylcysteine | 1 | 2020 | 255 | 0.04 | Why? |
| Paris | 1 | 2021 | 1287 | 0.04 | Why? |
| NF-E2-Related Factor 2 | 1 | 2020 | 373 | 0.04 | Why? |
| Platelet Transfusion | 1 | 2018 | 209 | 0.04 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.04 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.04 | Why? |
| Reactive Oxygen Species | 1 | 2020 | 1136 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| NF-kappa B | 1 | 2020 | 1301 | 0.03 | Why? |
| France | 2 | 2020 | 12074 | 0.03 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2018 | 11497 | 0.03 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.03 | Why? |
| HLA Antigens | 1 | 2018 | 830 | 0.03 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.03 | Why? |
| Extracellular Traps | 1 | 2020 | 1036 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Rosuvastatin Calcium | 1 | 2010 | 89 | 0.03 | Why? |
| Cytochrome P-450 CYP3A | 1 | 2010 | 88 | 0.03 | Why? |
| Oxidative Stress | 1 | 2020 | 2050 | 0.02 | Why? |
| Anticholesteremic Agents | 1 | 2010 | 186 | 0.02 | Why? |
| Aged | 3 | 2021 | 215776 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2020 | 4020 | 0.02 | Why? |
| Lymphocytes | 1 | 2020 | 3056 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.01 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.01 | Why? |
| Treatment Outcome | 2 | 2018 | 51732 | 0.01 | Why? |
| Combined Modality Therapy | 1 | 2010 | 3395 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 2010 | 3776 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Stroke | 1 | 2018 | 8839 | 0.01 | Why? |
Frère's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(155)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(70)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_